Publication | Closed Access

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

Breast OncologyMedicineSolid TumoursPathologyBreast CancerHer2 MutationsCancer TreatmentOncologyRadiation OncologyCancer Research